[Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro]

Jun Li1, Xiao-ming Yan

  • 1Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China.

Abstract

Insights

Olopatadine 0.1% eye drops demonstrated reduced toxicity to human corneal epithelial cells compared to ketotifen fumarate 0.025% and pemirolast potassium 0.1%. This suggests olopatadine may be a safer choice for treating allergic conjunctivitis long-term.

Area of Science:

  • Ophthalmology
  • Cell Biology
  • Toxicology

Context:

  • Allergic keratoconjunctivitis requires topical anti-allergic agents.
  • Evaluating the in vitro safety of these agents on corneal cells is crucial.
  • Olopatadine, ketotifen fumarate, and pemirolast potassium are common treatments.

Purpose:

  • To compare the in vitro cytotoxic effects of olopatadine 0.1%, ketotifen fumarate 0.025%, and pemirolast potassium 0.1% on human corneal epithelial cells.
  • To assess cell morphology, membrane permeability, esterase activity, and overall viability.

Summary:

  • Human corneal epithelial cells were exposed to the agents for varying durations and concentrations.
  • MTT assays and live-dead staining revealed olopatadine 0.1% induced significantly less cell damage and membrane permeability compared to the other agents.
  • Morphological analysis also indicated reduced cellular damage with olopatadine.

Impact:

  • Olopatadine 0.1% exhibits a more favorable safety profile for corneal epithelial cells in vitro.
  • This finding supports olopatadine as a potentially safer therapeutic option for prolonged treatment of allergic keratoconjunctivitis.
  • Further clinical studies can validate these in vitro safety observations.